highlights on pancreatic cancer - aiom.it · d a lla a lla highlights pancreatic cancer...
TRANSCRIPT
dalla
alla
Highlights Pancreatic Cancer
Dichiarazione potenziali conflitti di interessi
Consulente in advisory board/attività di formazione per:
- Lilly
- Astra Zeneca
- Celgene
- Italfarmaco
- Boehringer Ingelheim
dalla
alla
Highlights Pancreatic Cancer
Agenda
Trattamento neoadiuvante/adiuvante malattia resecabile
Caratterizzazione molecolare nella malattia avanzata
dalla
alla
Highlights Pancreatic Cancer
Agenda
Trattamento neoadiuvante/adiuvante malattia resecabile
dalla
alla
Highlights Pancreatic Cancer
Presented By Cristina Ferrone at 2019 Gastrointestinal Cancer Symposium
dalla
alla
Highlights Pancreatic Cancer
Terapia neoadiuvante nel rPC (e in parte brPC): studi randomizzati
Golcher, 2015 CTRT -> CH
CH 66 pts
17.4 m
14.4 m 0.96
Casadei, 2015 CTRT -> CH
CH 38 pts
22.4 m
19.5 m 0.973
Jang, 2018 CTRT -> CH -> CT
CH-> CTRT -> CT 57 pts
21 m
12 m 0.028
Preopanc, 2018 CT-> CTRT -> CH -> CT
CH -> CT 244 pts
17.1 m
13.7 m 0.074
PACT-15, 2018
CH -> CT
CH -> CT
CT -> CH -> CT
88 pts
20.4 m
26.4 m
38.2 m
NR
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05)
Presented By Michiaki Unno at 2019 Gastrointestinal Cancer Symposium
Prep-02/JSAP-05 phase II/III study
Presented By Michiaki Unno at 2019 Gastrointestinal Cancer Symposium
Study design and statistical analysis
Presented By Michiaki Unno at 2019 Gastrointestinal Cancer Symposium
Overall survival in Prep-01 study
Presented By Michiaki Unno at 2019 Gastrointestinal Cancer Symposium
Pathological findings (resected case)
Presented By Michiaki Unno at 2019 Gastrointestinal Cancer Symposium
Forest Plot on Overall Survival
Presented By Michiaki Unno at 2019 Gastrointestinal Cancer Symposium
dalla
alla
Highlights Pancreatic Cancer
Agenda
Trattamento neoadiuvante/adiuvante malattia resecabile
Caratterizzazione molecolare nella malattia avanzata
Genomic profiling in PDAC metastatic setting: <br />what do we know?
Presented By Grainne O'Kane at 2019 Gastrointestinal Cancer Symposium
Promising Outcomes in Targeting HR-DDR in Pancreatic Cancer
Presented By Michael Pishvaian at 2019 Gastrointestinal Cancer Symposium
HR-DDR Mutations are not Prognostically Favorable<br />in Platinum-Naïve Pancreatic Adenocarcinoma
Presented By Michael Pishvaian at 2019 Gastrointestinal Cancer Symposium
HR-DDR Deficiencies Predict OS Improvement<br />in Platinum-Treated Pancreatic Adenocarcinoma
Presented By Michael Pishvaian at 2019 Gastrointestinal Cancer Symposium
Overall survival according to modMoffitt and GATA6
Presented By Grainne O'Kane at 2019 Gastrointestinal Cancer Symposium
Estimated progression free survival according to chemo
Presented By Grainne O'Kane at 2019 Gastrointestinal Cancer Symposium
Overall survival according to chemotherapy
Presented By Grainne O'Kane at 2019 Gastrointestinal Cancer Symposium
Genomic Profiling: Actionable variants
Presented By Grainne O'Kane at 2019 Gastrointestinal Cancer Symposium
dalla
alla
Highlights Pancreatic Cancer
Conclusioni
Trattamento neoadiuvante malattia resecabile
Caratterizzazione molecolare nella malattia avanzata